Form 4: Akero Therapeutics CDO Sells Shares for Tax Obligations

Akero Therapeutics' Chief Development Officer, Catriona Yale, sold 659 shares of common stock at $43.02 per share to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Catriona Yale, Chief Development Officer of Akero Therapeutics, Inc. (AKRO), reported a sale of common stock.
• The transaction involved the disposition of 659 shares at a price of $43.02 per share.
• The sale was executed on September 11, 2025, and was reported on September 12, 2025.
• Following this transaction, Ms. Yale beneficially owns 90,829 shares of Akero Therapeutics common stock.
• The sale was non-discretionary, conducted to cover tax withholding obligations associated with the vesting of restricted stock units, under the company's "sell-to-cover" policy.

Sentiment

Score: 6

Explanation: The transaction is a routine, non-discretionary 'sell-to-cover' for tax purposes, stemming from the positive event of restricted stock unit vesting. While it reduces direct ownership, it is not indicative of a negative outlook by management.

Positives

• The underlying event, the vesting of restricted stock units, indicates compensation for the Chief Development Officer and aligns her interests with shareholders.
• The transaction was automatic and non-discretionary, indicating a routine tax-related event rather than a voluntary sale of shares.

Negatives

• A reduction in direct beneficial ownership by a key executive, even if for tax purposes, slightly decreases their direct equity stake.

Future Outlook

NA

Industry Context

This is a routine insider transaction filing and does not provide broader industry context or trends.

Stakeholder Impact

• Minimal impact on shareholders as this is a small, non-discretionary sale for tax purposes, not a signal of management's view on the company's prospects.
• Positive for the executive (Catriona Yale) as it represents the realization of compensation through RSU vesting.

Key Dates

Keywords

Akero Therapeutics, AKRO, Insider Trading, Form 4, Catriona Yale, Chief Development Officer, Stock Sale, Restricted Stock Units, Tax Withholding, Sell-to-Cover